U.S. Senate committee chair: Mylan's response on EpiPen price hike 'incomplete'
- Wall St. falls as earnings from some big names disappoint
- General Motors (GM) Tops Q3 EPS by 28c
- Procter & Gamble (PG) Tops Q1 EPS by 5c
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
- Pre-Open Stock Movers 10/25: (SAEX) (CWEI) (SWFT) Higher; (DPRX) (CRBP) (UA) Lower (more...)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
WASHINGTON (Reuters) - The chairman of the U.S. Senate Judiciary Committee probing Mylan NV's EpiPen price hike on Friday said its response to his query was "incomplete," and called on the drugmaker to give more details over how much government health insurance programs pay for the allergy treatment.
"It's an incomplete response and wouldn't satisfy my constituents who are upset about the EpiPen price increases. It doesn't provide the full picture that I requested, and it doesn't answer all of my questions," U.S. Senator Chuck Grassley said in a statement. He added that it is still unclear how many patients will benefit from Mylan's expanded assistance programme.
(Reporting by Susan Heavey, editing by G Crosse)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) Gains on Generic Concerta Approval
- Mylan (MYL), Theravance Biopharma(TBPH) Announce Positive Data from Two Revefenacin Phase 3s as COPD Treatment
- Q&A: How to keep a 127-year-old family business alive
Create E-mail Alert Related CategoriesGeneral News, Litigation, Reuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!